A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201)

Summary

The purpose of this research study is to assess the safety and efficacy of ALKS 2680 compared to placebo, including whether participants taking ALKS 2680 experience a greater decrease in sleepiness and a decrease in cataplexy ("sudden loss of muscle control"), compared to participants taking placebo alone.

Timeline

Start

2024-03-24

Primary completion

2025-06-19

Completion

2025-07-31

Outcome

Met primary endpoint

release “In Vibrance-1, alixorexton met the primary endpoint across all doses tested” alkermes.com ↗

Drugs

Indications